AdultPediatricDosage Forms & Strengths injectable solution 250mcg/mL Abortion Initial: 250 mcg IM; THEN repeat PRN q1.5-3.5hr OR An initial, optional test dose of 100 mcg IM; THEN increase dose to 500 mcg if response is inadequate with 250 mcg doses No more than 1200 mcg total dose or 2 days of continuous administration Refractory Postpartum Uterine Bleeding Initial 250 mcg IM, repeat PRN q15-90min No more than 2000 mcg or 8 dosesNot applicableInteraction CheckerEnter a drug name and carboprost tromethamineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (0)Monitor Closely (2)eluxadolineeluxadoline increases levels of carboprost tromethamine by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates.oxytocincarboprost tromethamine increases effects of oxytocin by pharmacodynamic synergism. Use Caution/Monitor.Minor (0)eluxadolineMonitor Closely (1)eluxadoline increases levels of carboprost tromethamine by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates.oxytocinMonitor Closely (1)carboprost tromethamine increases effects of oxytocin by pharmacodynamic synergism. Use Caution/Monitor. Frequency Not Defined Effects due to increased smooth muscle contractility most common Nausea (1/3 patients), Vomiting (~2/3 patients) Diarrhea (~2/3 patients) Nervousness Epistaxis Sleep disorder Hyperthermia Flushing Asthma Wheezing Coughing Chest pain Flushing Hypertension Syncope Palpation Tachycardia Chest tightness Anxiety Chills/shivering Dizziness Drowsiness Dystonia Faintness Headache Lethargy Lightheadedness Nervousness Sleep disturbance Temperature elevation Vasovagal syndrome Vertigo Rash Breast tenderness Dysmenorrhea-like pain Endometritis Hot flashes Thyroid storm Gagging/retching Drowsiness Dry throat Choking sensation Thirst Taste alterations Perforated uterus Posterior cervical perforation Urinary tract infection Uterine bleeding (excessive) Uterine rupture Uterine sacculation Local: injection site pain Backache Leg cramps Muscular pain Parethesia Torticollis Weakness Blurred vision Eye pain Eyelid twitching Tinnitus Cough Bronchospasm Dyspnea Hyperventilation Pulmonary edema Respiratory distress Upper respiratory tract infection Wheezing Diaphoresis Hiccups Retained placental fragment Septic shock Black Box Warning Potent oxytocic agent; use strict aderence to recommended dosing Only medically-trained personnel should administer the product in a hospital setting that can provide immediate care and acute surgical facilitiesContraindications Hypersensitivity Acute pelvic inflammatory disease Active cardiac, pulmonary, renal or hepatic disease Cautions History of glaucoma or raised IOP Asthma, hypertension/hypotension, cardiovascular disease Transient fever observed with treatment possibly as a result of carboprost's effect on hypothalamic thermoregulation Caution in patients with anemia, jaundice, renal impairment, hepatic impairment diabetes or epilepsy To decrease GI side effects pretreatment or concomitant use with antiemetic and antidiarrheal agents recommended Not for IV Rare cases of cardiovascular collapse reported with prostaglandins Pregnancy Category: C Lactation: Excretion in milk unknownPregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available. Mechanism of Action Inhibits or stimulates smooth muscle contraction, which results in expulsion of the products of conception and is used to induce abortion between 13-20 weeks of pregnancy; inhibits release of norepinephrine or modulates its effects at neuroeffector sites Pharmacokinetics Peak plasma time: 20-30 min Concentration: 1-1.6 ng/mL Half-life: 3 hr Protein bound: None Excretion: Urine BRAND FORM. UNIT PRICE PILL IMAGE Hemabate intramuscular- 250 mcg/mL solutionHemabate intramuscular- 250 mcg/mL solutioncarboprost tromethamine intramuscular- 250 mcg/mL vialcarboprost tromethamine intramuscular- 250 mcg/mL vialcarboprost tromethamine intramuscular- 250 mcg/mL vialCopyright © 2010 First DataBank, Inc.Print Patient Educationcarboprost tromethamine intramuscular NO MONOGRAPH AVAILABLE AT THIS TIME USES: Consult your pharmacist. HOW TO USE: Consult your pharmacist. SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345. PRECAUTIONS: Consult your pharmacist. DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist. OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. NOTES: No monograph available at this time. MISSED DOSE: Consult your pharmacist. STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product. Information last revised July 2016. Copyright(c) 2023 First Databank, Inc. IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs. FormularyPatient DiscountsAdding plans allows you to compare formulary status to other drugs in the same class.To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.Create Your List of PlansAdding plans allows you to:View the formulary and any restrictions for each plan.Manage and view all your plans together – even plans in different states.Compare formulary status to other drugs in the same class.Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions Tier Description 1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. NC NOT COVERED – Drugs that are not covered by the plan. Code Definition PA Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. QL Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. ST Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. OR Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. Plans Select State: Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming Done Non-Medicare Plans Medicare Plans Done CLOSE Additional Offers CLOSE Email to Patient From: To: The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send CLOSE Email Forms to Patient From: To: The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send